Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer Completes Acquisition of Wyeth
November 2, 2009
- Kyowa Kirin to Apply for KW-0761 Hopefully in 2011
November 2, 2009
- Roche to Strengthen Partnering in Japan: Mr McCracken
November 2, 2009
- REGULATORY NEWS IN BRIEF
November 2, 2009
- EP-Mint to Acquire Sogo SMO: EPS
November 2, 2009
- Lawmakers to Have Stronger Influence on Medical Fees
November 2, 2009
- BioWa Licenses POTELLIGENT Technology to NKTT
November 2, 2009
- 3 JMA Top Management Team Members Not Reappointed as Chuikyo Members
November 2, 2009
- Sanofi-aventis Licenses New Anti-Diabetic Agent from Wellstat Pharmaceuticals
November 2, 2009
- Price Maintenance System Essential to Make Drug Market in Japan More Attractive: Mr Kinosita
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -1-
November 2, 2009
- Korosho Increases FY2010 Budget Request to ¥28,889.4 Bil.
November 2, 2009
- Generics Use Rate by Far the Highest in Okinawa Prefecture
November 2, 2009
- Hatoyama Administration to Change Medical Expenditure Curtailment Policy
November 2, 2009
- Kyowa Kirin Transfers Neu-Up to Yakult
November 2, 2009
- Korosho to Issue Guidance for Transmission of Safety Information
November 2, 2009
- Medipal Ties Up with China's Largest Drug Wholesaler
November 2, 2009
- Bridion Recommended for Approval
November 2, 2009
- Terumo's Drug-Saving FN Syringe Approved in 3 Months
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -2-
November 2, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…